Bloomberg Law article on government scrutiny of the relationship between manufacturers and specialty pharma
An area that has garnered considerable government scrutiny of late is the relationships between pharmaceutical manufacturers and specialty pharmacies. In this two-part series, Bloomberg Law explores the development of the specialty pharmacy market and the risks as-sociated with these relationships and outline reasonable controls to mitigate the risks based upon re-cent enforcement actions.
In Part I of this two-part series, the evolving and wide-ranging role of specialty pharmacies in the dispensing of specialty drugs is covered, and the increased risks of government scrutiny and enforcement around them. In Part II of the series, we will provide answers to the critical questions around how manufacturers might reasonably mitigate the risks associated with this area of business.
This article features REGINA GORE CAVALIERE and EVAN BARTELL.